Estimating the clinical cost of drug development for orphan versus non-orphan drugs

Orphanet Journal of Rare Diseases

Volumn 14, Issue 1, 2019, Pages

  Jayasundara, Kavisha ^a   Hollis, Aidan ^b   Krahn, Murray ^a,c,e   Mamdani, Muhammad ^a,d,e   Hoch, Jeffrey S ^a,d,e,f   Grootendorst, Paul ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost of drug development; Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

ADULT; ARTICLE; CHILD; CLINICAL DEVELOPMENT PLAN; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; SOCIAL ASPECT; DRUG COST; DRUG DEVELOPMENT; DRUG MANUFACTURE; ECONOMICS; RARE DISEASE; STATISTICS AND NUMERICAL DATA;

DRUG COSTS; DRUG DEVELOPMENT; HEALTH EXPENDITURES; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 85059828850     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-018-0990-4     Document Type: Article

References (22)

1. Kumar Kakkar A, Dahiya N. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res. 2014;75(4):231-4.
2. Field MJ, B.T., editors, Rare Diseases and Orphan Products: Accelerating Research and Development. 2010, Washington (DC): National Academies Press (US).
3. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
4. EvaluatePharma, Orphan Drug Report 2017. 2017.
5. Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041-4.
6. Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13-14):660-4.
7. O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? Jama. 2013;310(13):1343-4.
8. Levy M, Rizansky Nir A. The pricing of breakthrough drugs: theory and policy implications. PLoS One. 2014;9(11):e113894.
9. Hollis A. Drugs for Rare Diseases: Paying for Innovation. In: Health services restructuring in Canada: new evidence and new directions. Montreal: McGill-Queen's University Press; 2006. p. 155-77.
10. (ASPE), O.o.t.A.S.f.P.a.E., Prescription Drugs: Innovation, Spending and Patient Access. 2016.
11. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33.
12. Prasad V, Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med. 2017;177(11):1569-75.
13. FDA Orphan Drug Database Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/.
14. Drugs@FDA Database. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
15. Practice BTP. Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies; 2015.
16. EvaluatePharma, Orphan Drug Report 2015. 2015.
17. Hay M, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
18. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9:170.
19. Mitsumoto J, et al. Pivotal Studies of Orphan Drugs Approved for Neurological Diseases. Annals of neurology. 2009;66(2):184-90.
20. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010;9(12):921-9.
21. Sharma A, et al. Orphan drug: Development trends and strategies. J Pharmacy and Bioallied Sciences. 2010;2(4):290-9.
22. Califf RM, et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012;307(17):1838-47.